A validated mass spectrometry method can screen for 41 small peptides and 3 growth hormone secretagogues in urine with zero false results across 5,000+ samples.
0 false resultsZero false positives and zero false negatives across more than 5,000 real urine samples tested with this method
What the researchers found
Researchers developed and validated a method using liquid chromatography with high-resolution mass spectrometry (LC-HRMS) in parallel reaction monitoring (PRM) mode to detect 41 small peptides and 3 non-peptide growth hormone secretagogues in human urine. The method achieved detection limits between 0.20 and 0.92 ng/mL, meeting all WADA minimum performance requirements.
The technique was validated on over 5,000 real urine samples with zero false positives and zero false negatives. The entire chromatographic run takes just 14 minutes, making it efficient for high-throughput anti-doping laboratories. The PRM mode dramatically reduces background noise from the urine matrix, improving both the reliability of screening and the accuracy of confirmation testing.
Why it matters
Peptide doping — using substances like growth hormone-releasing peptides, GnRH analogs, and other small peptides to enhance performance — is a growing concern in competitive sports. Detecting these substances in urine is technically challenging because peptides are present at very low concentrations and can be masked by the complex biological matrix. This validated method gives anti-doping labs a fast, reliable tool to catch peptide use, covering 44 prohibited substances in a single 14-minute run.
The numbers in context
41 small peptides + 3 non-peptide GH secretagogues · LOD 0.20–0.92 ng/mL · LOI 0.20–2.00 ng/mL · 14-min runtime · 5,000+ samples validated · 0 false positives · 0 false negatives
How the study worked
The researchers combined solid-phase extraction (SPE) sample preparation with LC-HRMS detection using parallel reaction monitoring (PRM) mode. They validated the method according to WADA criteria, testing selectivity, reliability, limits of detection and identification, recovery rates, extraction stability, and carryover. The method was then applied to over 5,000 real urine samples from doping control to verify real-world performance.
Who was studied
Over 5,000 human urine samples from doping control testing
What this study cannot tell us
The method focuses on small peptides and may not cover larger peptide hormones that require different analytical approaches. Detection limits, while meeting WADA requirements, vary across the 44 analytes. The study does not address how microdosing strategies or timing of peptide use might affect detection windows. Real-world applicability may also depend on individual lab equipment and operator expertise.
How to read the evidence
This is a rigorously validated analytical method tested against WADA criteria on over 5,000 real samples. The zero false-positive and false-negative rate across such a large sample set demonstrates exceptional reliability, earning a 'Strong' grade for method validation studies.
When this study was published
Published in 2021, this method is recent and reflects current analytical capabilities. Anti-doping methods evolve continuously, but the PRM approach described here represents the current state of the art for small peptide detection.
The bigger picture
As peptide drugs become more accessible — through online vendors, compounding pharmacies, and research chemical suppliers — the challenge of detecting their misuse in sports grows. Methods like this one give anti-doping authorities the analytical firepower to keep up with the expanding list of prohibited peptides, from growth hormone secretagogues to GnRH analogs and beyond.
Questions still open
- How short is the detection window for each of these peptides after a single dose?
- Can this method be adapted to detect newer peptides that emerge on the doping market?
- How does peptide microdosing affect the ability of even sensitive methods like this to catch cheaters?
Common questions
What kinds of peptides can this method detect?
How sensitive is this test compared to what WADA requires?
Read the original research
Doping control analysis of small peptides in human urine using LC-HRMS with parallel reaction monitoring mode: screening and confirmation.
Analytical methods : advancing methods and applications, 13(48), 5838-5850
Citation
Chang, Wei; He, Genye; Yan, Kuan; Wang, Zhanliang; Zhang, Yufeng; Dong, Tianyu; Liu, Yunxi; Zhang, Lisi; Hong, Liu. (2021). Doping control analysis of small peptides in human urine using LC-HRMS with parallel reaction monitoring mode: screening and confirmation.. Analytical methods : advancing methods and applications, 13(48), 5838-5850. https://doi.org/10.1039/d1ay01677f